大洋洲 · 综合新闻 · The Mercury
The quiet catalyst: Why open-label extension trials matter for ASX biotechs
While main trial results tend to attract the big headlines for biotech companies, lower-profile open-label extension (OLE) trials can tell an equally important story.
在 The Mercury 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.themercury.com.au)
